Navigation Links
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
Date:9/19/2007

es of Dynavax's HBV vaccine; the other group received three doses of Engerix-B.

Dynavax reported in mid-July 2007, that an international Phase 3 trial in Europe and Canada had completed enrollment. Data from the pivotal Phase 3 trial plus lot-to-lot consistency trials will contribute to a safety database of approximately 4,000 subjects for a planned BLA submission in 2008. Dynavax's HBV vaccine is based on its proprietary immunostimulatory sequence (ISS) that specifically targets Toll-Like Receptor 9 (TLR9) to stimulate an innate immune response. Dynavax's HBV vaccine combines ISS with HBV surface antigen (HBsAg) and is designed to significantly enhance the level, speed and longevity of protection. Dynavax indicates that as a result of its acquisition of Rhein Biotech in April 2006, the company has secured manufacturing capabilities in Dusseldorf, Germany for producing both clinical and initial commercial quantities of the hepatitis B surface antigen component of the vaccine.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV, a hepatitis B vaccine in Phase 3; TOLAMBA(TM), a ragweed allergy immunotherapy; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo,
'/>"/>

SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
4. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
5. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
7. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
8. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
9. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
10. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
11. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Chiasma, Inc. (NASDAQ: CHMA ), ... for the orphan condition acromegaly, today reported financial ... 2015 and provided a corporate update. ... time for Chiasma, as we successfully completed our ... first New Drug Application (NDA) has been accepted ...
(Date:8/31/2015)... 2015 With increasing clinical applications, the ... rise in active partnerships. The primary reason for ... quantitate CD4 cell markers in human immunodeficiency virus ... New analysis from Frost ... Market ( http://www.frost.com/nf0e ), finds the market earned ...
(Date:8/31/2015)... Aug. 31, 2015  The departments of Drug and ... at Gaudenzia Concept 90 to raise awareness for International ... in Pennsylvania and help more ... on recovery through the Building Bridges to Recovery ... dying every day to a disease that is fully ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2
... Identify Unique microRNA Signatures That Will ... Project Will Leverage Rosetta Genomics, Proprietary microRNA Extraction, and Quantification Technologies, ... and Experience ... Patients With High Risk, of Recurrence, who may Benefit From Adjuvant ...
... Accrual and Expansion Plans for SB-509-701 Phase 2 Clinical Trial for ... ... Neuropathy, SAN FRANCISCO, June 6 Sangamo BioSciences,Inc. (Nasdaq: SGMO ... trial (SB-509-701) in subjects with moderate to,severe diabetic neuropathy. Additionally, based upon ...
Cached Medicine Technology:Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 2Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 3Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 4Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer 5Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 2Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 3Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 4Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 5
(Date:9/1/2015)... ... September 01, 2015 , ... Elizabeth Callahan, MD, founder and medical director ... the area to offer RADIESSE® filler treatment for volume loss in the hands. RADIESSE ... and veins in the hands, delivering smooth, natural-looking results that can last up to ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, and ... and stickers to keep little ones' safety top of mind at all times. , ... particular focus. According to the JPMA's Baby Safety Zone website, this year's theme is ...
(Date:8/31/2015)... ... 2015 , ... The PT Outcomes Registry is an organized system for collecting ... The Registry is being developed by the American Physical Therapy Association (APTA). , Al ... selected to contribute FOTO Outcomes measures as one of the primary global outcomes measures ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... include a wealth of information for specific translation services within the medical and ... an incredible track record of successful work. , ITC Global Translations specializes in ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... their new β€œ InstantQuote ” tool, which summarizes all available plans, plan maximums, ... technology tool is designed to help India Network members make an informed decision ...
Breaking Medicine News(10 mins):Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2
... affecting Calcutta has arrived in Delhi and three deaths have ... weeks. //, ,In 2003 there were more than 30 ... reported. , ,N.K. Yadav, deputy health officer, Municipal Corporation ... control. They have hired 1,055 more health workers to check ...
... Cancer Institute had discovered a new molecular explanation for ... the disease called porphyria, the disease that was probably ... ,The Dana-Farber scientists say in a report featured ... the journal Cell that the nutritional component of porphyria ...
... a as paranormal phenomena, may in fact have their roots ... the high incidence of OBE among the general public, not ... of the population have an out-of-body experience (OBE) at some ... physical body from the outside. It isn't uncommon for people ...
... Indian Biotech Company, Biocon to colloborate with Nobex ... oral peptide drug for cardiovascular diseases. The spokesperson ... into global research collaboration // on Tuesday for ... cardiovasculoar diseases. The Biocon press release said, β€œThe ...
... in the September issue of the Harvard Health Letter, ... quick and short working out sessions may not help ... can lead to diseases. To prevent weight gain and ... sessions are required every week. ,Furthermore, some ...
... infection of newborns with herpes type 1 and 2 ... is not an established procedure in most cases., ... the // journal Sexually Transmitted Diseases, researchers in herpes ... STD in Seattle, point out that unlike all comparable ...
Cached Medicine News:Health News:Study Unveils New Insight To The Madness Of King George III 2Health News:Experts Insist That Neonatal Herpes Be Reported Regularly 2
... therapeutic, expandable turning surface for the BariMaxx™ ... Prevention and treatment of pressure ulcers, Large ... patients using a statuc mattress that would ... whose body weight and size pose a ...
... 300 is a healthcare bed system which ... in the home care setting, ,INDICATIONS: ... weight of 2) ,Healthcare frame accommodating ... size selected, ,CONTRAINDICATIONS: ,Total weight in ...
... A Bariatric bed providing a flexible environment ... relief mattress system for comfort, support, treatment ... up to 850 lbs. ,Large patients at ... using a static mattress that would benefit ...
... Rest Deluxe Transport beds feature folding head end and ... storage. With the head end and foot end deck ... reduced to approximately 67". This compact length makes storage, ... ,This feature is not available on Model 4748B, ...
Medicine Products: